




Recommendations for Aspirin and Oral P2Y12 Inhibitors in Patients Undergoing PCI Referenced studies that support the recommendations are summarized in Online Data Supplement 32.

COR	LOE	RECOMMENDATIONS
1	B-R	1. In patients undergoing PCI, a loading dose of aspirin, followed by daily dosing, is recommended to reduce ischemic events (1-4).*
1	B-R	2. In patients with ACS undergoing PCI, a loading dose of P2Y12 inhibitor, followed by daily dosing, is recommended to reduce ischemic events (5-15).
1	C-LD	3. In patients with SIHD undergoing PCI, a loading dose of clopidogrel, followed by daily dosing, is rec- ommended to reduce ischemic events (8,12,15-19).
1	C-LD	4. In patients undergoing PCI within 24 hours after fibrinolytic therapy, a loading dose of 300 mg of clo- pidogrel, followed by daily dosing, is recommended to reduce ischemic events (5).
2a	B-R	5. In patients with ACS undergoing PCI, it is reasonable to use ticagrelor or prasugrel in preference to clopidogrel to reduce ischemic events, including stent thrombosis (6,14,20).
2b	B-R	6. In patients <75 years of age undergoing PCI within 24 hours after fibrinolytic therapy, ticagrelor may be a reasonable alternative to clopidogrel to reduce ischemic events (21).
3: Harm	B-R	7. In patients undergoing PCI who have a history of stroke or transient ischemic attack, prasugrel should not be administered (6).
CAL FORUM A TO Z		

CVRE




 In selected patients undergoing PCI, shorter-duration DAPT (1-3 months) is reasonable, with subsequent trasition to P2Y12 inhibitor monotherapy to reduce the risk of bleeding events (2a).

 In patients undergoing PCI, discontinuation of P2Y12 after 3mo (SIHD) or 6mo (ACS) may be reasonable (2b).



Lawton et al. 2021 ACC/AHA/SCAI Coronary Revascularization Guideline




 In selected patients undergoing PCI, shorter-duration DAPT (1-3 months) is reasonable, with subsequent trasition to P2Y12 inhibitor monotherapy to reduce the risk of bleeding events (2a).

Discontinuation of aspirin after 1–3 mo with continued P2Y12 monotherapy (2a)



Lawton et al. 2021 ACC/AHA/SCAI Coronary Revascularization Guideline






COMPLEX PCI 2023 MAKE IT SIMPLEI; TECHNICAL FORUM A TO Z

Lawton et al. 2021 ACC/AHA/SCAI Coronary Revascularization Guideline

TRITON-TIMI 38 Trial *Prasugrel vs. Clopidogrel in patients with ACS*



The primary efficacy end point was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke.

The key safety end point was major bleeding.



Stephen D. Wiviott et al. N Engl J Med. 2007;357:2001-15.

TRITON-TIMI 38 Trial

Prasugrel vs. Clopidogrel in patients with ACS

Table 2. Major Efficacy End Points in the Overall Cohort at 15 Months.*

End Point	Prasugrel (N=6813)	Clopidogrel (N = 6795)	Hazard Ratio for Prasugrel (95% CI)	P Value†
	no. of par	tients (%)		
Death from cardiovascular causes, nonfatal MI, or nonfatal stroke (primary end point)	643 (9.9)	781 (12.1)	0.81 (0.73-0.90)	<0.001
Death from cardiovascular causes	133 (2.1)	150 (2.4)	0.89 (0.70–1.12)	0.31
Nonfatal MI	475 (7.3)	620 (9.5)	0.76 (0.67–0.85)	<0.001
Nonfatal stroke	61 (1.0)	60 (1.0)	1.02 (0.71–1.45)	0.93
Death from any cause	188 (3.0)	197 (3.2)	0.95 (0.78–1.16)	0.64
Death from cardiovascular causes, nonfatal MI, or urgent target-vessel revascularization	652 (10.0)	798 (12.3)	0.81 (0.73-0.89)	<0.001
Death from any cause, nonfatal MI, or nonfatal stroke	692 (10.7)	822 (12.7)	0.83 (0.75–0.92)	<0.001
Urgent target-vessel revascularization	156 (2.5)	233 (3.7)	0.66 (0.54–0.81)	<0.001
Death from cardiovascular causes, nonfatal MI, nonfatal stroke, or rehospitalization for ischemia	797 (12.3)	938 (14.6)	0.84 (0.76–0.92)	<0.001
Stent thrombosis‡	68 (1.1)	142 (2.4)	0.48 (0.36–0.64)	<0.001

Stephen D. Wiviott et al. N Engl J Med. 2007;357:2001-15.

CVRF

TRITON-TIMI 38 Trial *Prasugrel vs. Clopidogrel in patients with ACS*

Table 3. Thrombolysis in Myocardial Infarction (TIMI) Bleeding End Points in the Overall Cohort at 15 Months.*

End Point	Prasugrel (N=6741)	Clopidogrel (N=6716)	Hazard Ratio for Prasugrel (95% CI)	P Value
	no. of pat	ients (%)		
Non–CABG-related TIMI major bleeding (key safety end point)	146 (2.4)	111 (1.8)	1.32 (1.03–1.68)	0.03
Related to instrumentation	45 (0.7)	38 (0.6)	1.18 (0.77–1.82)	0.45
Spontaneous	92 (1.6)	61 (1.1)	1.51 (1.09–2.08)	0.01
Related to trauma	9 (0.2)	12 (0.2)	0.75 (0.32–1.78)	0.51
Life-threatening†	85 (1.4)	56 (0.9)	1.52 (1.08–2.13)	0.01
Related to instrumentation	28 (0.5)	18 (0.3)	1.55 (0.86–2.81)	0.14
Spontaneous	50 (0.9)	28 (0.5)	1.78 (1.12–2.83)	0.01
Related to trauma	7 (0.1)	10 (0.2)	0.70 (0.27–1.84)	0.47
Fatal‡	21 (0.4)	5 (0.1)	4.19 (1.58–11.11)	0.002
Nonfatal	64 (1.1)	51 (0.9)	1.25 (0.87–1.81)	0.23
Intracranial	19 (0.3)	17 (0.3)	1.12 (0.58–2.15)	0.74
Major or minor TIMI bleeding	303 (5.0)	231 (3.8)	1.31 (1.11–1.56)	0.002
Bleeding requiring transfusion§	244 (4.0)	182 (3.0)	1.34 (1.11–1.63)	<0.001
CABG-related TIMI major bleeding¶	24 (13.4)	6 (3.2)	4.73 (1.90–11.82)	<0.001


CVRF

Stephen D. Wiviott et al. N Engl J Med. 2007;357:2001-15.

8™ COMPLEX PCI 2023 MAKE IT SIMPLEI: TECHNICAL FORUM A TO :

PLATO Trial

Ticagrelor vs. Clopidogrel in patients with ACS




The primary end point - a composite of death from vascular causes, myocardial infarction, or stroke – occurred significantly less often in the ticagrelor group than in the clopidogrel group (9.8% vs. 11.7% at 12months; hazard ratio, 0.84; 95% confidence interval, 0.77 to 0.92; P<0.001).



Lars Wallentin et al. N Engl J Med. 2009;361:1045-57.

PLATO Trial

Ticagrelor vs. Clopidogrel in patients with ACS




The time was estimated from the first dose of the study drug in the safety population. The hazard ratio for major bleeding, defined according to the study criteria, for the ticagrelor group as compared with the clopidogrel group was 1.04 (95% confidence interval, 0.95 to 1.13).



Lars Wallentin et al. N Engl J Med. 2009;361:1045-57.

TWILIGHT Trial

Ticagrelor with or without Aspirin in High-Risk patients after PCI




Kaplan-Meier Estimates of the Incidence of BARC Type 2, 3, or 5 Bleeding 1 Year The hazard ratio shown is for ticagrelor plus placebo versus ticagrelor plus aspirin. Bleeding Academic **Research Consortium** (BARC) types range from 0 (no bleeding) to 5 (fatal bleeding).



COMPLEX PCI 2023 MAKE IT SIMPLEI: TECHNICAL FORUM A TO Z

TWILIGHT Trial

Ticagrelor with or without Aspirin in High-Risk patients after PCI



Kaplan-Meier Estimates of the Incidence of Death from Any Cause, Nonfatal MI, or **Nonfatal Stroke 1 Year** The per-protocol population included patients who underwent randomization and had no major deviations from the protocol. The hazard ratio shown is for ticarelor plus placebo versus ticarelor



8[™] COMPLEX PCI 2023 MAKE IT SIMPLEI: TECHNICAL FORUM A TO 2

R. Mehran, U. Baber et al. N Engl J Med. 2019;381:2032-42.

plus aspirin.

TWILIGHT Trial

Ticagrelor with or without Aspirin in High-Risk patients after PCI

Table 2. Bleeding and Ischemic Events 1 Year after Randomization.*						
Variable	Ticagrelor plus Placebo (N = 3555)	Ticagrelor plus Aspirin (N = 3564)	Hazard Ratio (95% CI)†	P Value		
	no. of pat	ients (%) <u>‡</u>				
Bleeding end points						
Primary end point: BARC type 2, 3, or 5	141 (4.0)	250 (7.1)	0.56 (0.45–0.68)	<0.001¶		
BARC type 3 or 5∬	34 (1.0)	69 (2.0)	0.49 (0.33–0.74)			
TIMI minor or major	141 (4.0)	250 (7.1)	0.56 (0.45–0.68)			
GUSTO moderate or severe	26 (0.7)	49 (1.4)	0.53 (0.33–0.85)			
ISTH major	39 (1.1)	72 (2.1)	0.54 (0.37–0.80)			
Ischemic end points						
Death from any cause, nonfatal myocardial infarction, or nonfatal stroke	135 (3.9)	137 (3.9)	0.99 (0.78–1.25)	<0.001		
Death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal ischemic stroke	126 (3.6)	130 (3.7)	0.97 (0.76–1.24)			
Death from any cause	34 (1.0)	45 (1.3)	0.75 (0.48–1.18)			
Death from cardiovascular causes	26 (0.8)	37 (1.1)	0.70 (0.43–1.16)			
Myocardial infarction	95 (2.7)	95 (2.7)	1.00 (0.75–1.33)			
Ischemic stroke	16 (0.5)	8 (0.2)	2.00 (0.86–4.67)			
Stent thrombosis, definite or probable	14 (0.4)	19 (0.6)	0.74 (0.37–1.47)			

Among high-risk patients who underwent PCI and completed 3 months of dual antiplatelet therapy, ticagrelor monotherapy was associated with a lower incidence of clinically relevant bleeding than ticagrelor plus aspirin, with no higher risk of death, myocardial infarction, or stroke.



COMPLEX PCI 2023 MAKE IT SIMPLEI: TECHNICAL FORUM A TO Z

DAPT Duration After Implantation of DES





DAPT Duration After Implantation of DES

Study	Year*	Trial Completion	Primary Study Endpoint	Trial Design and Outcome	Expected Event Rate in Control Group (%)	Observed Event Rate in Control Group (%)	Proportion With Newer- Generation DES (%)
DES LATE (12 vs. 36 mo) (13)	2010	Extension of ZEST-LATE and REAL-LATE (12)	Cardiac death, MI, or stroke <24 h	Superiority not shown	2.7	2.6	30
PRODIGY (6 vs. 24 mo) (14,15)	2012	Enrollment completed	Death, MI, or stroke	Superiority not shown	8.0	10.1	67
EXCELLENT (6 vs. 12 mo) (16)	2012	Enrollment completed	Cardiac death, MI, or ischemia-driven TVR	Noninferiority confirmed	10.0	4.5	75
RESET (3 vs. 12 mo) (17)	2012	Enrollment completed	Cardiac death, MI, ST, revasc, or bleeding	Noninferiority confirmed	10.5	4.7	85
OPTIMIZE (3 vs. 12 mo) (18)	2013	Enrollment completed	NACCE-death, MI, stroke, or bleed	Noninferiority confirmed	9.0	6.0	100
ARCTIC Interruption (12 vs. 18 mo) (19)	2014	Extension of ARCTIC (39)	Death, MI, ST, stroke, or urgent TVR	Superiority not shown	6.0	4.0	63
SECURITY (6 vs. 12 mo) (20)	2014	Stopped after 1,399 enrolled of 2,740 planned	Cardiac death, MI, ST, or stroke	Noninferiority confirmed	4.5	4.5	100
ITALIC (6 vs. 24 mo) (21)	2015	Stopped after 2,031 enrolled of 2,475 planned	Death, MI, urgent TVR, stroke, or major bleeding	Noninferiority confirmed	3.0	1.5	100
ISAR-SAFE (6 vs. 12 mo) (22)	2015	Stopped after 4,005 enrolled of 6,000 planned	Death, MI, ST, stroke, or TIMI major bleed	Noninferiority confirmed	10.0	1.5	72
DAPT (12 vs. 30 mo) (23)	2015	Enrollment completed	Coprimary: ST and MACCE	Superiority shown	0.5/2.9	0.5/2.4	59
OPTIDUAL (12 vs. 48 mo) (24)	2015	Stopped after 1,385 enrolled of 1,966 planned	Death, MI, stroke, or major bleed	Superiority not shown	7.0	7.5	59




Bittl et al. J Am Coll Cardiol. 2016 Sep 6;68(10):1116-39.


DAPT Duration After Implantation of DES Forest Plot of Endpoints After 12 Months Versus <u>Shorter Courses</u>

3-6 Months vs. 12 Months

A Mortality



C Myocardial infarction




8™ COMPLEX PCI 2023 MAKE IT SIMPLEI: TECHNICAL FORUM A TO 2

Bittl et al. J Am Coll Cardiol. 2016 Sep 6;68(10):1116-39.

DAPT Duration After Implantation of DES

FIGURE 3 Forest Plot of Mortality Rates in 11 RCTs After Stent Implantation




Bittl et al. J Am Coll Cardiol. 2016 Sep 6;68(10):1116-39.

CVRF

DAPT Duration After Implantation of DES

A Overall




B History of Acute Coronary Syndromes




C No History of Acute Coronary Syndrome

Bittl et al. J Am Coll Cardiol. 2016 Sep 6;68(10):1116-39.




Effect of P2Y12 Inhibitor Monotherapy vs DAPT after PCI





Young Bin Song et al. Am Heart J. 2018;197:77-84.

Effect of P2Y12 Inhibitor Monotherapy vs DAPT after PCI




 Results of the analysis of the primary end point of major adve rse cardiovascular and cerebro vascular events (a composite of death, myocardial infarction, or stroke) at 12 months.

 Cumulative rates of MACCE at 12 months were 2.9% for the P2Y12 inhibitor monotherapy group and 2.5% for the DAPT group (difference, 0.4%; P = .007 for noninferiority of P2Y12 monotherapy)



Effect of P2Y12 Inhibitor Monotherapy vs DAPT after PCI




Results of the randmark analysis at 3 months (the point after which one group received P2Y12 inhibitor only and the other received DAPT) for the primary end point.

 The risk of MACCE between 3 and 12 months was not significantly different between the group (hazard ratio, 1.14; 95% CI, 0.67-1.93; P = .63)



Effect of P2Y12 Inhibitor Monotherapy vs DAPT after PCI




Results of the analysis of the bleeding at 12 months.

The rate of bleeding was significantly lower in the P2Y12 inhibitor monotherapy group than in the DAPT group (2.0% vs 3.4%; hazard ratio, 0.58 ; 95% Cl, 0.36-0.92; P = .02)



Effect of P2Y12 Inhibitor Monotherapy vs DAPT after PCI




Results of the landmark analysis at 3 months (the point after which one group received P2Y12 inhibitor only and the other received DAPT) for bleeding.

 There was no significant difference in the risk of bleeding between the groups in the post hoc 3-month landmark anlaysis (hazard ratio, 0.59; 95% Cl, 0.34-1.01; P = 0.053)



TICO Trial

Effect of Ticagrelor mono vs Ticagrelor with Aspirin in patients with ACS



The primary outcome


A 1-year net adverse clinical event; a composite of major bleeding and adverse cardiac and cerebrovascular events (death, MI, stent thrombosis, stroke, or TVR)



Choongki Kim et al. Am Heart J. 2019;212:45-52.

TICO Trial

Effect of Ticagrelor mono vs Ticagrelor with Aspirin in patients with ACS



1529 1500 1489 1481 1466 1460 1455 1442 1432 1430 1423 1418 1407

1527 1498 1483 1471 1462 1456 1452 1442 1437 1437 1432 1430 1424

 The primary outcome of a net adverse clinical event occurred in 59 patients (3.9%) receiving ticagrelor monotherapy after 3month DAPT and in 89 patients (5.9%) receiving ticagrelor-based 12month **DAPT** (absolute difference, -1.98%) [95% Cl, -3.50% to -0.45%]; HR, 0.66 [95% Cl, 0.48 to 0.92]; P = .01)

12-mo DAP


3-mo DAPT

CVRF

Byeong-Keuk Kim et al. JAMA. 2020;323(23):2407-2416.

TICO Trial

Effect of Ticagrelor mono vs Ticagrelor with Aspirin in patients with ACS



 On prespecified 3-month landmark analyses between 3 and 12 months, a net adverse clinical event occurred in 21 patients (1.4%) receiving ticagrelor monotherapy after 3month DAPT and in 51 patients (3.5%) receiving ticagrelorbased 12-month DAPT (HR, 0.41 [95% Cl, 0.25 to 0.68]; P = 0.001)


CVRF

No. at risk

12-mo DAPT 1529 1500 1489 1481 1466 1460 1455 1442 1432 1430 1423 1418 1407 3-mo DAPT 1527 1498 1483 1471 1462 1456 1452 1442 1437 1437 1432 1430 1424


Byeong-Keuk Kim et al. JAMA. 2020;323(23):2407-2416.

Effect of 1M DAPT followed by clopidogrel vs 12M DAPT after PCI



Watanabe et al., JAMA 2019;321:2414

Effect of 1M DAPT followed by clopidogrel vs 12M DAPT after PCI




The primary end point occurred in 35 patients (2.36%) in the 1M DAPT occurred in 55 patients (3.70%) in the 12M DAPT • 1M DAPT to 12M DAPT (absolute difference, -1.34%) [95% Cl, -2.57% to -0.11%]; HR, 0.64 [95% CI, 0.42-0.98]; P < .001 for noninferiority; P = .04 for superiority)



Hirotoshi Watanabe et al. JAMA. 2019;321(24):2414-2427.

Effect of 1M DAPT followed by clopidogrel vs 12M DAPT after PCI




For the major secondary cardiovascular end point • 1M DAPT to 12M DAPT (1.96% vs 2.51%; absolute difference, -0.55% [95% Cl, -1.62% to -0.52%]; HR, 0.79 [95% CI, 0.49-1.29]; P = .005 for noninferiority; P = .34 for superiority)



Hirotoshi Watanabe et al. JAMA. 2019;321(24):2414-2427.

Effect of 1M DAPT followed by clopidogrel vs 12M DAPT after PCI



For the major secondary bleeding end point
1M DAPT to 12M DAPT (0.41% vs 1.54%;


absolute difference, -1.13% [95% CI, -1.84% to -0.42%]; HR, 0.26 [95% CI, 0.11-0.64]; *P* = .004)



Hirotoshi Watanabe et al. JAMA. 2019;321(24):2414-2427.

P2Y12 inhibitor monotherapy or DAPT after PCI

: Individual patient level meta-analysis of RCTs



 For primary endpoint of all cause death, myocardial infarction, or stroke in intention to treat population.

Fig 1 | Hazard ratios for individual trials and for pooled population and Kaplan-Meier estimates for primary endpoint of all cause death, myocardial infarction, or stroke in intention to treat population. Kaplan-Meier curves and hazard ratios from one step, fixed effect meta-analysis (top) and two step, fixed effect meta-analysis (bottom). DAPT=dual antiplatelet therapy; P2Y12i=P2Y₁₂ inhibitor monotherapy



P2Y12 inhibitor monotherapy or DAPT after PCI


: Individual patient level meta-analysis of RCTs

	P2Y12i monotherapy (%) (n=11 634)	DAPT (%) (n=11 674)	Hazard ratio (95% CI)	P value fo interactio	
Primary outcome				<u>\</u>	
Clopidogrel	60/2618 (2.5)	65/2650 (2.7)		0.16	0.94 (0.66 to 1.33)
Newer P2Y12i	243/9016 (2.9)	273/9024 (3.4)	_		0.89 (0.75 to 1.06)
All cause mortality					
Clopidogrel	29/2618 (1.2)	27/2650 (1.1)		0.16	1.09 (0.65 to 1.84)
Newer P2Y12i	78/9016 (0.9)	110/9024 (1.4)	_		0.71 (0.53 to 0.95)
Myocardial infarction					
Clopidogrel	19/2618 (0.8)	23/2650 (1.0)	• • • • • • • • • • • • • • • • • • •	0.23	0.84 (0.46 to 1.54)
Newer P2Y12i	148/9016 (1.8)	158/9024 (1.9)			0.94 (0.75 to 1.17)
Stroke					
Clopidogrel	15/2618 (0.6)	17/2650 (0.7)	• • • • • • • • • • • • • • • • • • •	0.40	0.90 (0.45 to 1.79)
Newer P2Y12i	36/9016 (0.5)	28/9024 (0.3)	• • • • • • • • • • • • • • • • • • •		1.29 (0.79 to 2.11)
BARC 3 or 5					
Clopidogrel	19/2618 (0.8)	32/2650 (1.3)	◆	0.41	0.60 (0.34 to 1.06)
Newer P2Y12i	78/9016 (0.9)	165/9024 (1.9)	_		0.47 (0.36 to 0.62)
			0.25 0.50 1	2	
			P2Y12i monotherapy better DAPT bette	er	

Fig 4 | Primary endpoint or its components and key safety endpoint stratified by use of clopidogrel or newer P2Y₁₂ inhibitors in experimental arm of intention to treat population. BARC=Bleeding Academy Research Consortium; DAPT=dual antiplatelet therapy

Marco Valgimigli et al. BMJ. 2021 Jun 16;373:n1332.

P2Y12 inhibitor monotherapy or DAPT after PCI : Individual patient level meta-analysis of RCTs



 For safety endpoint of BARC type 3 or type 5 in intention to treat population.

Fig 5 | Hazard ratios for individual trials and for pooled population and Kaplan-Meier estimates for key safety endpoint of Bleeding Academic Research Consortium (BARC) type 3 or type 5 bleeding in intention to treat population. Kaplan-Meier curves and hazard ratios from one step, fixed effect meta-analysis (top) and two step, fixed effect meta-analysis (bottom). DAPT=dual antiplatelet therapy

AKE IT SIMPLEI: TECHNICAL FORUM A TO Z



Aspirin versus Clopidogrel





CAPRIE Trial

Clopidogrel vs Aspirin in patients at risk of ischaemic events





Figure 2: Participant progress through trial

8[™]

HOST-EXAM Trial

Aspirin vs Clopidogrel for chronic maintenance monotherapy after PCI



• Participants

≥ 20 years old

underwent PCI with DES and maintained DAPT without any clinical events within 6-18 months after PCI

Exclusion

any ischaemic and major bleeding complications (non-fatal MI, any repeat revascularization, readmission due to cardiac cause, and major bleeding

Bon-Kwon Koo et al. Lancet. 2021 Jun 26;397(10293):2487-2496.

Aspirin vs Clopidogrel for chronic maintenance monotherapy after PCI


	Clopidogrel (n=2710)	Aspirin (n=2728)	Hazard ratio (95% CI)*	p value
Primary composite endpoint†	152 (5.7%)	207 (7.7%)	0.73 (0.59-0.90)	0.003
Thrombotic composite endpoint‡	99 (3.7%)	146 (5.5%)	0.68 (0.52-0.87)	0.003
Any bleeding (BARC type ≥2)§	61 (2.3%)	87 (3.3%)	0.70 (0.51-0.98)	0.036
All-cause death¶	51 (1·9%)	36 (1-3%)	1.43 (0.93–2.19)	0.101
Cardiac death	19 (0.7%)	14 (0.5%)	1.37 (0.69-2.73)	0.374
Non-cardiac death	32 (1·2%)	22 (0.8%)	1.47 (0.85-2.52)	0.167
Non-fatal myocardial infarction	18 (0.7%)	28 (1.0%)	0.65 (0.36–1.17)	0.150
Stroke	18 (0.7%)	43 (1-6%)	0.42 (0.24-0.73)	0.002
Ischaemic stroke	14 (0.5%)	26 (1.0%)	0.54 (0.28–1.04)	0.064
Haemorrhagic stroke	4 (0.2%)	17 (0.6%)	0.24 (0.08-0.70)	0.010
Readmission due to ACS	66 (2.5%)	109 (4.1%)	0.61 (0.45-0.82)	0.001
Major bleeding (BARC type ≥3)	33 (1.2%)	53 (2.0%)	0.63 (0.41-0.97)	0.035
Any revascularisation	56 (2.1%)	69 (2.6%)	0.82 (0.57-1.16)	0.261
Target lesion revascularisation	24 (0.9%)	36 (1-4%)	0.67 (0.40-1.12)	0.130
Target vessel revascularisation	37 (1.4%)	48 (1.8%)	0.78 (0.50-1.19)	0.245
Definite or probable stent thrombosis	10 (0.4%)	16 (0.6%)	0.63 (0.29–1.39)	0.251
Any minor gastrointestinal complications	272 (10·2%)	320 (11-9%)	0.85 (0.72-1.00)	0.048



Bon-Kwon Koo et al. Lancet. 2021 Jun 26;397(10293):2487-2496.

Aspirin vs Clopidogrel for chronic maintenance monotherapy after PCI


• A) The cumulative incidence of the primary endpoint, consisting of all-cause death, non-fatal MI, stroke, readmission due to ACS, and major bleeding (BARC 3 or more) complications



Bon-Kwon Koo et al. Lancet. 2021 Jun 26;397(10293):2487-2496.

Aspirin vs Clopidogrel for chronic maintenance monotherapy after PCI

• B) The cumulative incidence of the secondary composite thrombotic endpoint, consisting of cardiac death, non-fatal MI, ischaemic stroke, readmission due to ACS, or definite or probable stent thrombosis




MAKE IT SIMPLEI: TECHNICAL FORUM A TO Z

Bon-Kwon Koo et al. Lancet. 2021 Jun 26;397(10293):2487-2496.

Aspirin vs Clopidogrel for chronic maintenance monotherapy after PCI

• C) The cumulative incidence of any bleeding events.




Bon-Kwon Koo et al. Lancet. 2021 Jun 26;397(10293):2487-2496.

Safety and efficacy with P2Y12 inhibitor monotherapy after initial period of DAPT(1 to 3 months)

versus

Standard DAPT in patients undergoing complex and noncomplex PCI



COMPLEX PCI 2023 Make it simple:: technical forum a to

Felice Gragnano et al. J Am Coll Cardiol. 2023 Feb, 81(6)537-552.


CVRE

A) Primary Efficacy Endpoint

(All-cause death, MI, and Stroke)

B) Key Safety Endpoint

(BARC Type 3 or 5 Bleeding)




Felice Gragnano et al. J Am Coll Cardiol. 2023 Feb, 81(6)537-552.

365

823

A) All-Cause Mortality

B) Cardiovascular Mortality




8™ COMPLEX PCI 2023 Make It simplei: technical forum a to z

Felice Gragnano et al. J Am Coll Cardiol. 2023 Feb, 81(6)537-552.

C) Myocardial Infarction

D) Stroke




8™ COMPLEX PCI 2023 Make It simplei: technical forum a to 2

Felice Gragnano et al. J Am Coll Cardiol. 2023 Feb, 81(6)537-552.


• E) Definite or Probable Stent Thrombosis

F) Net Adverse Clinical Events (NACE)



8™ COMPLEX PCI 2023 Make it simple1: technical forum a to z

Felice Gragnano et al. J Am Coll Cardiol. 2023 Feb, 81(6)537-552.






Gragnano F, et al. J Am Coll Cardiol. 2023;81(6):537-552.



Aspirin vs Clopidogrel for long term maintenance monotherapy after PCI






Jeehoon Kang et al. Circulation. 2023;147:108-117.

Aspirin vs Clopidogrel for long term maintenance monotherapy after PCI


• A) The cumulative incidence of the primary endpoint, consisting of all-cause death, non-fatal MI, stroke, readmission due to ACS, and major bleeding (BARC 3 or more) complications



Jeehoon Kang et al. Circulation. 2023;147:108-117.

Aspirin vs Clopidogrel for long term maintenance monotherapy after PCI

• B) The cumulative incidence of the secondary composite thrombotic endpoint, consisting of cardiac death, non-fatal MI, ischaemic stroke, readmission due to ACS, or definite or probable stent thrombosis






Jeehoon Kang et al. Circulation. 2023;147:108-117.

Aspirin vs Clopidogrel for long term maintenance monotherapy after PCI


• C) The cumulative incidence of any bleeding events.



Jeehoon Kang et al. Circulation. 2023;147:108-117.


Aspirin vs Clopidogrel for long term maintenance monotherapy after PCI

• D) The cumulative incidence of all-cause death.










ADI F


Marco Valgimigli et al. Eur Heart J. 2018 Jan 14;39(3):213-260.

CENTRAL ILLUSTRATION Recommendations for Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention



8TH COMPLEX PCI 2023 MAKE IT SIMPLEI: TECHNICAL FORUM A TO Z






co



TAILORED-CHIP Trial

Tailored P2Y12 Strategy for CHIP patients



Time after PCI

Figure 1. Timing of ischemic versus bleeding events after PCI. Ischemic and bleeding rates after PCI are displayed dependent on time. Whereas ischemic rates reach a plateau during the first month, bleeding rates steadily decline. In the second month, ischemic events substantially decrease resulting in an exuberant bleeding risk in the later phase post-PCI.


PCI = percutaneous coronary intervention.

MAKE IT SIMPLEI: TECHNICAL FORUM A TO

Danny Kupka et al. Korean Circ J. 2018 Oct;48(10):863-872.




TAILORED-CHIP TrialTailored P2Y12 Strategy for CHIP patients



Ticagrelor 60 mg might provide better safety and tolerability than ticagrelor 90 mg
 with similar efficacy in East Asian patients with ACS. From OPTIMA trial
 MALE X POLICY ALL
 MALE X SIMPLE: TECHNICAL FORMATOZ

TAILORED-CHIP Trial

Tailored P2Y12 Strategy for CHIP patients




*Complex High-Risk PCI

: Left main PCI, chronic total occlusion, bifurcation requiring two-stent technique, severe calcification, diffuse long lesion (lesion length \ge 30mm), multivessel PCI (\ge 2 vessels requiring stent implantation), \ge 3 requiring stents implantation, \ge 3 lesions will be treated, predicted total stent length for revascularization >60mm, diabetes, CKD (Cr-clearance <60ml/min) or severe LV dysfunction (EF <40%).



P2Y12 inhibitor: Switching Ticagrelor to Clopidogrel at 6 month



"At 24 hours from last dose of ticagrelor, clopidogrel 600 mg loading dose should be given"

Antiplatelet Therapy in Patients with Anticoagulation





Antiplatelet Therapy in Patients with an Indication for Oral Anticoagulation Undergoing PCI

COR	LOE	RECOMMENDATIONS				
1	B-R	1. In patients with atrial fibrillation who are undergoing PCI and are taking oral anticoagulant therapy, recommended to discontinue aspirin treatment after 1 to 4 weeks while maintaining P2Y12 inhibitor				
		addition to a non-vitamin K oral anticoagulant (rivaroxaban, dabigatran, apixaban, or edoxaban) or warfarin to reduce the risk of bleeding (1-7).				
		2. In patients with atrial fibrillation who are undergoing PCI, are taking oral anticoagulant therapy, and are				
2a	B-R	treated with DAPT or a P2Y12 inhibitor monotherapy, it is reasonable to choose a non-vitamin K oral anticoagulant over warfarin to reduce the risk of bleeding (1,3,4).				
		anticoagutant over warrann to reduce the risk of bleeding (1,5,4).				






Lawton et al. 2021 ACC/AHA/SCAI Coronary Revascularization Guideline

Antiplatelet Therapy in Patients with an Indication for Oral Anticoagulation Undergoing PCI

Patients with an indication for oral anticoagulation undergoing PCI¹




8™ COMPLEX PCI 2023 MAKE IT SIMPLEI: TECHNICAL FORUM A TO Z

Marco Valgimigli et al. 2017 ESC focused update on DAPT in coronary artery disease

CVRE

Antiplatelet Therapy in Patients with an Indication for Oral Anticoagulation Undergoing PCI



Gerhard Hindricks et al. 2020 ESC Guidelines for atrial fibrillation

Antiplatelet Therapy in Patients with an Indication for Oral Anticoagulation Undergoing PCI

THROMBOTIC RISK FACTORS

- · Diabetes mellitus requiring therapy
- Prior ACS/recurrent myocardial infarction
- Multivessel CAD
- Concomitant PAD
- Premature CAD (occurring at age of <45 y) or accelerated CAD (new lesion within 2 years)
- CKD (eGFR <60 mL/min)
- Clinical presentation (ACS)
- Multivessel stenting
- Complex revascularisation (left main stenting, bifurcation lesion stenting, chronic total occlusion intervention, last patent vessel stenting)
- Prior stent thrombosis on antiplatelet treatment
- Procedural factors (stent expansion, residual dissection, stent length, etc.)

BLEEDING RISK FACTORS

- Hypertension
- Abnormal renal or liver function
- Stroke or ICH history
- Bleeding history or bleeding diathesis (e.g., anaemia with haemoglobin <110 g/L)
- Labile INR (if on VKA)
- Elderly (>65 years)
- Drugs (concomitant OAC and antiplatelet therapy, NSAIDs), excessive alcohol consumption

STRATEGIES TO REDUCE BLEEDING ASSOCIATED WITH PCI


- Radial artery access
- PPIs in patients taking DAPT who are at increased risk of bleeding (e.g., the elderly, dyspepsia, gastro-oesophageal reflux disease, Helicobacter pylori infection, chronic alcohol use)
- Non-administration of unfractionated heparin in patients on VKA with INR >2.5
- Pre-treatment with aspirin only, add a $\mathsf{P2Y}_{12}$ inhibitor when coronary anatomy is known or if STEMI
- GP IIb/IIIa inhibitors only for bailout or periprocedural complications
- Shorter duration of combined antithrombotic therapy



Gerhard Hindricks et al. 2020 ESC Guidelines for atrial fibrillation

Antithrombotic Therapy after ACS or PCI in Atrial Fibrillation

Apixaban Versus Warfarin in Patients with AF and ACS and/or PCI: The AUGUSTUS Trial



Primary outcome: major/clinically relevant non-major bleeding (through 6 months) Key secondary outcome: All-cause death and all-cause hospitalization


Other secondary outcomes: Death, MI, stroke, stent thrombosis, urgent revascularization, hospitalization

CVRF

Renato D. Lopes et al. Am Heart J. 2018 Jun;200:17-23.

Antithrombotic Therapy after ACS or PCI in Atrial Fibrillation

A Primary Outcome — Apixaban vs. Vitamin K Antagonist



Primary outcome was major or clinically relevant nonmajor bleeding defined by the International

Society on Thrombosis and Haemostasis.

Apixaban




Renato D. Lopes et al. N Engl J Med. 2019;380:1509-24.

Antithrombotic Therapy after ACS or PCI in Atrial Fibrillation

B Primary Outcome — Aspirin vs. Placebo

Aspirin

Placebo



Primary outcome was major or clinically relevant nonmajor bleeding defined by the International


Society on Thrombosis and Haemostasis.



Renato D. Lopes et al. N Engl J Med. 2019;380:1509-24.

Antithrombotic Therapy after ACS or PCI in Atrial Fibrillation

C Primary Outcome, According to Intervention Combination



Days since Start of Intervention


No. at Risk							
Vitamin K antagonist and aspirin	1123	962	881	838	800	776	467
Apixaban and aspirin	1145	1036	975	937	903	880	485
Vitamin K antagonist and placebo	1126	1007	947	917	883	851	528
Apixaban and placebo	1143	1075	1044	1007	975	947	536

Primary outcome was major or clinically relevant nonmajor bleeding defined by the International MAKEIT STOCIETY ON² Thrombosis and Haemostasis. Renato D. Lopes et al. N Engl J Med. 2019;380:1509-24.



Antithrombotic Therapy after ACS or PCI in Atrial Fibrillation

A Death or Hospitalization — Apixaban vs. Vitamin K Antagonist






Renato D. Lopes et al. N Engl J Med. 2019;380:1509-24.

Antithrombotic Therapy after ACS or PCI in Atrial Fibrillation

B Death or Hospitalization — Aspirin vs. Placebo






Aspirin

Placebo

Renato D. Lopes et al. N Engl J Med. 2019;380:1509-24.

Antithrombotic Therapy after ACS or PCI in Atrial Fibrillation


C Death or Hospitalization, According to Intervention Combination



CONTLEATURE

8TH

Safety and Efficacy of Antithrombotic Strategies in Patients with AF after PCI: Meta-analysis of RCTs




8TH COMPLEX PCI 2023 MAKE IT SIMPLEI: TECHNICAL FORUM A TO Z Renato D. Lopes et al. JAMA Cardiol. 2019;4(8):747-755.

Safety and Efficacy of Antithrombotic Strategies in Patients with AF after PCI: Meta-analysis of RCTs

3

Α TIMI major bleeding

		N
Odds ratio (95% CI)		
VKA + DAPT (reference)		
VKA + P2Y ₁₂ inhibitor	0.58 (0.31-1.08)	
NOAC + DAPT	0.70 (0.38-1.23)	
NOAC + P2Y ₁₂ inhibitor	0.49 (0.30-0.82)	




Odds Ratio for TIMI Major Bleeding

Faura wa

В TIMI major and minor bleeding

Odds ratio (95% CI)				
0.49 (0.26-0.92)				
0.63 (0.33-1.17)				
0.43 (0.25-0.76)				



and Minor Bleeding

RF

Trial-defined primary safety outcome С

Odds ratio (95% CI)		Favors Nonreference Strategy	Favors Reference
VKA + DAPT (reference)		1	
VKA + P2Y ₁₂ inhibitor	0.45 (0.21-0.92)		
NOAC + DAPT	0.64 (0.31-1.31)		
NOAC + P2Y ₁₂ inhibitor	0.47 (0.25-0.85)		2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
		0	1 2

Odds Ratio for Trial-Defined Primary Safety Outcome




Odds ratio (95% CI)		Favors Nonreference Strategy	Favors Reference	
VKA + DAPT (reference)				
VKA + P2Y ₁₂ inhibitor	1.44 (0.40-5.22)			
NOAC + DAPT	0.54 (0.15-1.92)			
NOAC + $P2Y_{12}$ inhibitor	0.26 (0.08-0.79)			
		0 1	2	3
			dds Ratio for ranial Hemorrhage	

Renato D. Lopes et al. JAMA Cardiol. 2019;4(8):747-755.

Safety and Efficacy of Antithrombotic Strategies in Patients with AF after PCI: Meta-analysis of RCTs


A Trial-defined primary MACE

		1
Odds ratio (95% CI)		
VKA + DAPT (reference)		
VKA + P2Y ₁₂ inhibitor	0.96 (0.60-1.46)	
NOAC + DAPT	0.94 (0.60-1.15)	
NOAC + P2Y ₁₂ inhibitor	1.02 (0.71-1.97)	



В	All-cause death
---	-----------------

Odds ratio (95% CI)			
0.84 (0.40-1.56)			
1.04 (0.54-1.98)			
1.02 (0.59-1.74)			



Odds Ratio for All-Cause Death

c Cardiovascular death

Odds ratio (95% CI)		Favors Nonreference Strategy	Favo Refe
VKA + DAPT (reference)			
VKA + P2Y ₁₂ inhibitor	0.82 (0.42-1.49)		
NOAC + DAPT	0.94 (0.53-1.63)		
NOAC + P2Y ₁₂ inhibitor	1.11 (0.70-1.75)		-
		0 1	

Favors eference Favors Strategy Reference

3

Odds Ratio for Cardiovascular Death

D Myocardial infarction

Odds ratio (95% CI)	Nonreference Strategy	Favors Reference	
VKA + DAPT (reference)			
VKA + P2Y ₁₂ inhibitor	1.25 (0.77-1.99)	_	
NOAC + DAPT	1.13 (0.72-1.78)		-
NOAC + P2Y ₁₂ inhibitor	1.18 (0.81-1.72)	_	
		0	1 2

Odds Ratio for Myocardial Infarction

Renato D. Lopes et al. JAMA Cardiol. 2019;4(8):747-755.


3

Safety and Efficacy of Antithrombotic Strategies in Patients with AF after PCI: Meta-analysis of RCTs

F


E Stroke

Odds ratio (95% CI)			
VKA + DAPT (reference)			
VKA + P2Y ₁₂ inhibitor	1.02 (0.36-2.65)		
NOAC + DAPT	0.91 (0.35-2.32)		
NOAC + P2Y ₁₂ inhibitor	0.77 (0.34-1.67)		



Odds ratio (95% CI)			
VKA + DAPT (reference)			
VKA + P2Y ₁₂ inhibitor	1.08 (0.46-2.31)		
NOAC + DAPT	0.93 (0.40-2.17)		
NOAC + P2Y ₁₂ inhibitor	1.41 (0.71-2.76)		

Stent thrombosis



Odds Ratio for Stent Thrombosis

G Hospitalization


Odds ratio (95% CI)		Favors Nonreference Strategy	Favors Reference
VKA + DAPT (reference)			
VKA + P2Y ₁₂ inhibitor	0.86 (0.57-1.23)		
NOAC + DAPT	0.80 (0.55-1.13)		
NOAC + P2Y ₁₂ inhibitor	0.80 (0.59-1.08)		
		0 1	1 2

Odds Ratio for Hospitalization



Renato D. Lopes et al. JAMA Cardiol. 2019;4(8):747-755.

Safety and Efficacy of Antithrombotic Strategies in Patients with AF after PCI: Meta-analysis of RCTs



- A regimen of NOACs plus P2Y12 inhibitor was associated with less bleeding compared with VKAs plus DAPT.
- Strategies omitting aspirin caused less bleeding, including intracranial bleeding, without significant difference in MACE, compared with strategies including aspirin.
- Our results support the us of NOAC plus P2Y12 inhibitor as the preferred regimen post-percutaneous coronary intervention for these high-risk patients with AF.
- A regimen of VKA plus DAPT should generally be avoided.

Renato D. Lopes et al. JAMA Cardiol. 2019;4(8):747-755.


AFIRE Early Termination of the Trial

- The evaluation of the patients was planned to continue until September 2018.
- Because of a higher risk of death from any cause in the combination-therapy group, the independent data and safety monitoring committee recommended early termination of the trial in July 2018.
- > The median treatment duration was 23.0 months (interquartile range, 15.8 to 31.0)
- > The median follow-up period was 24.1 months (interquartile range, 17.3 to 31.5)






Primary Efficacy Endpoint* (CV Events or Death)



Bayer does not recommend off-label use of products. Before prescribing any products, please consult the relevant local prescribing information.

Yasuda S et al, N Engl J Med 2019;381:1103-1113

Primary Safety Endpoint (Major Bleeding)*




Bayer does not recommend off-label use of products. Before prescribing any products, please consult the relevant local prescribing information.

Yasuda S et al, N Engl J Med 2019;381:1103-1113

Secondary Efficacy Endpoints

Lower rate of all-cause mortality for rivaroxaban monotherapy versus combination therapy (HR=0.55; 95% CI 0.38–0.81), due to lower incidences of both CV and non-CV death Trial terminated early because of higher risk of death in the combination therapy group The most common causes of death were heart failure, stroke and cancer




Bayer does not recommend off-label use of products. Before prescribing any products, please consult the relevant local prescribing information. *Unstable angina requiring revascularization; #composite of death from any cause, myocardial infarction, unstable angina requiring revascularization, stroke, transient ischaemic attack, systemic arterial embolism, venous thromboembolism, revascularization or stent thrombosis

Yasuda S et al, N Engl J Med 2019;381:1103-1113

Other Secondary Endpoints

Lower rate of net clinical AEs* for rivaroxaban monotherapy versus combination therapy (HR=0.62; 95% CI 0.47–0.82)

Lower rate of non-major bleeding events for rivaroxaban monotherapy versus combination therapy (HR=0.58; 95% CI 0.46–0.72)



*Composite of death from any cause, myocardial infarction, stroke or major bleeding, transient ischaemic attack, systemic arterial embolism, venous thromboembolism, revascularization or stent thrombosis (AKE IT SIMPLE: TECHNICAL FORUMATIC AN Engl J Med 2019;381:1103–1113) (AKE IT SIMPLE: TECHNICAL FORUMATIC AN Engl J Med 2019;381:1103–1113)


Subgroup Analysis for Primary Efficacy Endpoint

		Mon		rapy		mbina Therap r patie) Hazard	Ratio(95% CI)			Rivaroxaban Monotherapy no. / total no. (9	Combination Therapy 6 per patient-year)	Hazard	d Ratio(95% CI)
Total							(5.8)	+++	0.72 (0.55-0.95)						
Total										Use of	Yes	54 / 663 (4.2)	82 / 694 (6.3)	++-	0.68 (0.48-0.95)
	Male	66 /	875	(3.9)	95	/ 876	(5.7)	H	0.68 (0.50-0.93)	PPI	No	35 / 444 (4.0)	39 / 414 (4.8)	-	0.83 (0.53-1.32)
Sex							(5.9)		0.90 (0.51-1.58)						
										Previous	Yes	63 / 847 (3.8)	100 / 850 (6.2)		0.62 (0.45-0.85)
Age	<75 years								0.89 (0.56-1.42)	PCI or CABG	No	26 / 260 (5.1)	21 / 258 (4.3)		1.19 (0.67-2.11)
	≥75 years	56 /	582	(5.0)	84	/ 581	(7.8)	H+-	0.64 (0.46-0.91)						
			FOR	(40	1 500	(DES	38 / 500 (3.9)	48 / 477 (5.3)	-	0.75 (0.49-1.15)
Type of	Paroxysma			the subscription of the				H++	0.74 (0.48-1.14)	Type of	BMS	13 / 171 (3.8)	25 / 171 (7.4)		0.52 (0.27-1.02)
AF	Persistent							•	0.51 (0.26-1.00)	Stent	DES+B	MS 5 / 19 (15.0)	6 / 36 (10.0)	⊢ ∔•	1.49 (0.45-4.88)
	Permanent	397	347	(5.7)	4/	/ 353	(6.9)	-	0.85 (0.55-1.30)	_					
Diabetes	Ver	45 /	461	(5 1)	65	1 166	(7.5)		0.69 (0.46, 0.00)	CHADS ₂	1	9 / 230 (2.0)	13 / 241 (2.8)		0.72 (0.31-1.68)
mellitus	Yes No						(4.5)		0.68 (0.46-0.99) 0.77 (0.52-1.14)	score	2 to 6	80 / 874 (4.7)	108 / 865 (6.6)	H+t	0.72 (0.54-0.96)
menitus	NO		040	(3.3)	50	1 042	(4.5)		0.77 (0.52-1.14)						
(Constants of the second seco	<30	11/	54	(11.8)	14	/ 60	(14.0)		0.87 (0.39-1.94)	CHA-DSVASC	O to 3	22 / 429 (2.6)	31 / 436 (3.6)		0.71 (0.41-1.23)
CrCl	30 to 50	39 /					(8.3)	-	0.83 (0.54-1.29)	score	≥4	67 / 678 (5.2)	90 / 672 (7.2)	H+i	0.72 (0.52-0.99)
(ml/min)	≥50						(4.5)		0.57 (0.38-0.87)	-				1	Contraction of the Section of the
										Constant of the second second	0 or 1	16 / 224 (3.6)	17 / 193 (4.6)		0.79 (0.40-1.56)
Rivaroxaban	10 mg od	52 /	497	(5.5)	72	/ 513	(7.5)	i i i i i i i i i i i i i i i i i i i	0.73 (0.51-1.05)	HAS-BLED	2		71 / 583 (6.2)		0.62 (0.42-0.91)
dose	15 mg od								0.70 (0.45-1.08)	score	3 to 5	28 / 283 (5.2)	32 / 290 (6.1)	-	0.86 (0.52-1.42)
							1		1				1		1
							0.1	1	10				0.1	1	10
							-		\rightarrow						
						Fa	vors		Favors				Favors		Favors
					N	lono	therap	ру	Combination Therapy				Monotherap	Y	Combination Therapy

COMPLEX PCI 2023 MAKE IT SIMPLE: TECHNICAL FORUMA TO Z Yasuda S et al, ZN Engl J Med 2019;381:1103–1113



AF-PCI Trials among NOACs




CVRF

COMPL Gibson CM et al, New Engl J Med 2016; doi: 10.1056/NEJMoa1611594 2. Christopher PC et al, New Engl J Med 2017; 377:1513-1524 MAKE IT SIMPLEF ECHNICAL FORM A 10, New Engl J Med 2019; DOI: 10.1056/NEJMoa1817083 4. Vranckx P et al, American Heart Journal. 2018;196:105-112

Edoxaban-based long-term antithrombotic therapy with AF and CAD

(Edoxaban versus Edoxaban with antiPlatelet agent In patients with atrial fibrillation and Chronic stable Coronary Artery Disease)

EPIC-CAD trial





Edoxaban-based long-term antithrombotic therapy with AF and CAD

Inclusion criteria

- 1. Patients aged ≥18 y
- 2. Patients with AF with high embolic risk (CHA2DS2-VASc score ≥ 2)
- 3. Patients with stable CAD

• Coronary revascularization (either PCI or CABG) at least 6 mo for stable angina or at least 1 y for ACS before study enrollment

• Anatomically confirmed (with ≥50% stenosis of major coronary artery by CAG or coronary CTA on optimal medical therapy not requiring revascularization



Edoxaban-based long-term antithrombotic therapy with AF and CAD

Exclusion criteria

- 1. Patients with thrombocytopenia (<50,000/uL)
- 2. High risk of bleeding prohibiting anticoagulant use according to the attending physician's discretion (ie, baseline comorbidities, hyper- or hypocoagulable state, increased prothrombin time, or activated partial thromboplastin time)
- 3. Prior history of intracranial hemorrhage
- 4. Mechanical prosthetic valve or moderateto-severe mitral stenosis

5. Patients contraindicated for edoxaban or antiplatelets

- 6. Planned PCI or CABG within 1 y after randomization
- 7. Liver cirrhosis or liver dysfunction (AST or ALT > ×3 of normal range or coagulation abnormality)
- 8. Creatinine clearance <30 mL/min
- 9. Life expectancy <12 mo</p>
- 10. Patients unable to provide written informed consent or participate in long-term follow-up
- 11. Pregnant or lactating women
- 12. Patients actively participating in another drug or device investigational study

Edoxaban-based long-term antithrombotic therapy with AF and CAD

Primary endpoint

 Net clinical outcomes – composites of allcause death, stroke, systemic embolic event, myocardial infarction, unplanned revascularization of the major coronary artery, and major bleeding or clinically relevant nonmajor bleeding event

8™ COMPLEX PCI 2023 MAKE IT SIMPLEI: TECHNICAL FORUM A TO

Secondary endpoints

- Efficacy outcomes
 - 1) All-cause death
 - 2) Cardiovascular death
 - 3) Myocardial infarction
 - 4) Ischemic stroke
 - 5) Systemic embolism
 - 6) Unplanned revascularization
- 7) Composite of hard clinical endpoints (all-cause death, myocardial infarction, ische mic stroke, and systemic embolism)
 8) Stent thrombosis (in patients who under
- went coronary stenting)



Edoxaban-based long-term antithrombotic therapy with AF and CAD

Secondary endpoints

Safety outcomes

 Composite of major or clinically relevant nonmajor bleeding during follow-up as defined by the International Society on Thrombosis and Hemostasis (ISTH)
 Fatal bleeding (ISTH, BARC 5)
 Major bleeding (ISTH, BARC 3, TIMI major bleeding)

4) Clinically relevant nonmajor bleeding (ISTH, BARC, and TIMI criteria)
5) Any bleeding (ISTH, BARC, and TIMI criteria)
6) Intracranial hemorrhage
7) Gastrointestinal hemorrhage



ADORE Trial

Evaluation of Routine Functional Testing after PCI

TABLE 2Functional Test Results of Patients Who Underwent Routine FunctionalTesting

	Timing of Fu	Timing of Functional Test			
Test Result	6 Wks	6 Mon*			
No. of METs achieved (mean ± SD) Mean maximum predicted heart rate achieved Maximum predicted heart rate ≥85% Electrically or clinically positive Electrically, clinically, or imaging positive [†] Electrically and clinically negative	9 ± 3% 91 ± 19% 66% 23% - 60%	$9 \pm 3\%$ 89 $\pm 18\%$ 65% 30% 38% 57%			

TABLE 3 Functional Test Results at Nine Months*

	Functional Te		
Test Result	Routine	Selective	p Value
No. of METs achieved (mean \pm SD) Mean maximum predicted heart rate achieved Maximum predicted heart rate \geq 85% Electrically or clinically positive Electrically and clinically negative	10 ± 3% 90 ± 21% 68% 20% 69%	9 ± 3% 91 ± 16% 69% 22% 70%	0.09 0.87 0.89 0.76 0.89




Mark J. Eisenberg et al. Am J Cardiol. 2004;93:744-747.



ADORE Trial

Evaluation of Routine Functional Testing after PCI



8TH COMPLEX PCI 2023 MAKE IT SIMPLEI: TECHNICAL FORUM A TO Z

Mark J. Eisenberg et al. Am J Cardiol. 2004;93:744-747.




Stopping Aspirin Within 1 Month After Stenting for Ticagrelor Monotherapy in Acute Coronary Syndrome

- Aim: asess non-inferiority of < 1 month DAPT followed by ticagrelol monotherapy vs 12 month DAPT in ACS.
- Design: non inferiority RCT of 2850 patients with ACS who underwent PCI with DES in 24 south Korean centres.
- primary endpoint: composite of all-cause death, myocardial infarction, definite or probable stent thrombosis, stroke, and major bleeding at 1 year after the index procedure



Sung-Jin Hong, Circulation. 2023








Sung-Jin Hong, Circulation. 2023






Sung-Jin Hong, Circulation. 2023



COMPLEX PCI 2023 MAKE IT SIMPLEI: TECHNICAL FORUM A TO Z



COMPLEX PCI 2023 MAKE IT SIMPLEI: TECHNICAL FORUM A TO Z

Sung-Jin Hong, Circulation. 2023




	No. /To	otal (%)				<i>P</i> value for interaction
Subgroup	Ticagrelor monotherapy after <1-month DAPT	Ticagrelor- based 12-month DAPT	HR (95% CI)	Favors Fa	Favors 12-month DAPT	
All patients	40/1426 (2.8)	73/1424 (5.2)	0.54 (0.37-0.80)			
Age, years						0.67
<65	17/888 (1.9)	29/901 (3.2)	0.59 (0.33-1.08)	⊢		
≥65	23/538 (4.3)	44/523 (8.5)	0.50 (0.30-0.83)	⊢_∎		
Sex						0.52
Men	33/1193 (2.8)	56/1181 (4.8)	0.58 (0.38-0.89)	⊢_∎		
Women	7/233 (3.0)	17/243 (7.1)	0.42 (0.18-1.02)	⊢		
Diabetes mellitus						0.09
Yes	17/422 (4.1)	19/408 (4.7)	0.87 (0.45-1.68)	⊢	<u> </u>	
No	23/1004 (2.3)	54/1016 (5.3)	0.43 (0.26-0.70)		-	
Hypertension					Heart Association	0.67
Yes	21/669 (3.2)	42/679 (6.2)	0.51 (0.30-0.85)			
No	19/757 (2.5)	31/745 (4.2)	0.60 (0.34-1.06)			
Chronic kidney disease						0.23
Yes ded No	10/118 (8.6)	10/104 (9.7)	0.87 (0.36-2.10)			
aded No	30/1308 (2.3)	63/1320 (4.8)	0.48 (0.31-0.74)			
ST-elevation MI						0.93
Multivessel disease	16/572 (2.8)	29/578 (5.0)	0.56 (0.30-1.02)	<u>⊢</u>		
ahaj. No	24/854 (2.8)	44/846 (5.2)	0.54 (0.33-0.88)			
Multivessel disease						0.58
Jes Yes	25/749 (3.4)	49/738 (6.7)	0.50 (0.31-0.81)			
Yes No	15/677 (2.2)	24/686 (3.5)	0.63 (0.33-1.20)	⊢ ■	4	
₹otal stent length, mm						0.86
afotal stent length, mm ≥30 III <30	24/791 (3.1)	45/788 (5.7)	0.53 (0.32-0.87)	┝──╋───┤│		
≓ <30	16/635 (2.5)	28/636 (4.4)	0.57 (0.31-1.05)	⊢ −		
gascular access for PCI						0.90
Transradial	22/959 (2.3)	41/954 (4.3)	0.53 (0.32-0.89)	⊢		
Transfemoral	18/467 (3.9)	32/470 (6.8)	0.56 (0.32-0.98)	├ ─── ■ ───┤		
				0.2 0.5 1	2 5	



Sung-Jin Hong, Circulation. 2023



Twilight-Ticagrelol induced Dyspnea



Angiolillo DJ, et al. J Am Cardio 2023;16(20): 2514-2524

CVRF